Fulminant hepatitis after carbimazole and propranolol administration.
We report the case of a patient who developed jaundice, encephalopathy, a marked increase in serum aminotransferase activity and a decrease in prothrombin and proaccelerin levels, after 6 weeks' treatment with carbimazole and propranolol for hyperthyroidism. The patient ultimately underwent orthotopic liver transplantation. This case strongly suggests that carbimazole may occasionally induce fulminant hepatitis and that careful monitoring of liver enzymes may be useful during the treatment of hyperthyroidism with this drug.
Epeirier
J M
JM
Service d'Hépato-gastroentérologie, Hôpital Saint Eloi, Montpellier, France.
Pageaux
G P
GP
Coste
V
V
Perrigault
P F
PF
Banc
P
P
Larrey
D
D
Michel
H
H
D000319:Adrenergic beta-Antagonists / Q000009:adverse effects*; D000410:Alanine Transaminase / Q000097:blood; D013956:Antithyroid Agents / Q000009:adverse effects*; D001219:Aspartate Aminotransferases / Q000097:blood; D002231:Carbimazole / Q000009:adverse effects*; D056486:Chemical and Drug Induced Liver Injury / Q000097:blood / Q000209:etiology*; D005165:Factor V / Q000032:analysis; D005260:Female; D006501:Hepatic Encephalopathy / Q000097:blood / Q000139:chemically induced*; D006801:Humans; D007565:Jaundice / Q000097:blood / Q000139:chemically induced*; D016031:Liver Transplantation; D008875:Middle Aged; D011433:Propranolol / Q000009:adverse effects*; D011516:Prothrombin / Q000032:analysis
D000319:Adrenergic beta-Antagonists; D013956:Antithyroid Agents; D002231:Carbimazole; D005165:Factor V; D011516:Prothrombin; D011433:Propranolol; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase